Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical Cancer Research

• Publication date

  2018-04-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-18-0565PMID 29674508PMCID PMC6195480
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

  2017cited by this paper
• Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.

  2016cited by this paper
• Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

  2016influential reference
• Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

  2016cited by this paper
• Improved overall survival in melanoma with combined dabrafenib and trametinib.

  2015cited by this paper
• XL888 limits vemurafenib-induced proliferative skin events by suppressing paradoxical MAPK activation

  2015cited by this paper
• Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.

  2015cited by this paper
• Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

  2015cited by this paper
• HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo

  2015cited by this paper
• BRAF inhibition generates a host/tumor niche that mediates therapeutic escape

  2015cited by this paper
• A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

  2014cited by this paper
• Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics

  2014cited by this paper
• Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

  2014cited by this paper
• First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors

  2014cited by this paper
• Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib

  2014cited by this paper
• MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

  2014cited by this paper
• First-inHuman Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP 90 Inhibitor , AT 13387 , in Patients with Advanced Solid Tumors

  2014cited by this paper
• Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics*

  2014cited by this paper
• Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

  2014cited by this paper
• Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

  2014cited by this paper
• Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

  2014influential reference
• Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

  2013cited by this paper
• Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.

  2013influential reference
• Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma

  2013cited by this paper
• A landscape of driver mutations in melanoma.

  2012cited by this paper
• Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

  2012cited by this paper
• A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma

  2012cited by this paper
• The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

  2012influential reference
• Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion

  2012cited by this paper
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

  2012cited by this paper
• Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

  2012cited by this paper
• HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

  2011cited by this paper
• A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

  2011cited by this paper
• RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010influential reference
• Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

  2010influential reference
• Targeting the dynamic HSP90 complex in cancer

  2010cited by this paper
• Geldanamycin selectively targets the nascent form of ERBB3 for degradation

  2010cited by this paper
• A modified toxicity probability interval method for dose-finding trials

  2010cited by this paper
• Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

  2009cited by this paper
• MEK1 mutations confer resistance to MEK and B-RAF inhibition

  2009cited by this paper
• Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

  2008cited by this paper
• Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

  2008cited by this paper
• Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

  2006cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.

  2005influential reference
• Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments

  year unknowncited by this paper

• Advances in the structures, mechanisms and targeting of molecular chaperones

  2025cites this paper
• Overcoming cancer drug resistance through small-molecule targeting of HSP90 and HSP70

  2025cites this paper
• Heat Shock Proteins in Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Identification of UBE3C as an E3 ubiquitin ligase for mutant BRAF.

  2025cites this paper
• Oncogenic stress response mechanisms as new therapeutic targets in cancer treatment: A review

  2025cites this paper
• Strong Hsp90α/β Protein Expression in Advanced Primary CRC Indicates Short Survival and Predicts Response to the Hsp90α/β-Specific Inhibitor Pimitespib

  2025cites this paper
• A Phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling.

  2025cites this paper
• Identification of drug candidates against glioblastoma with machine learning and high-throughput screening of heterogeneous cellular models

  2025cites this paper
• XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial

  2025cites this paper
• Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress

  2024cites this paper
• Distinct patterns of proteostasis network gene expression are associated with different prognoses in melanoma patients

  2024cites this paper
• CRISPR-StAR enables high-resolution genetic screening in complex in vivo models

  2024cites this paper
• Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma

  2024cites this paper
• A biodegradable lipid nanoparticle delivers a Cas9 ribonucleoprotein for efficient and safe in situ genome editing in melanoma.

  2024cites this paper
• An update on the status of HSP90 inhibitors in cancer clinical trials.

  2024cites this paper
• Regulation of RAF family kinases: new insights from recent structural and biochemical studies

  2024cites this paper
• Molecular Pathways Governing the Termination of Liver Regeneration

  2024cites this paper
• Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment

  2023cites this paper
• Dose‐escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF‐mutant solid tumors

  2023cites this paper
• Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

  2023cites this paper
• Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio-N-arylacetamides as novel HSP90 C-terminal inhibitors

  2023cites this paper
• Human peripheral blood mononuclear cells as a valuable source of disease‐related biomarkers: Evidence from comparative proteomics studies

  2023cites this paper
• High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

  2023cites this paper
• Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer

  2023cites this paper
• Synergistic induction of apoptosis in liver cancer cells: exploring the combined potential of doxorubicin and XL-888

  2023cites this paper
• Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600‐mutant melanoma

  2023cites this paper
• BRAFΔβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability

  2023cites this paper
• DUSP4 promotes esophageal squamous cell carcinoma progression by dephosphorylating HSP90β.

  2023cites this paper
• Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening

  2022cites this paper
• HSP90 inhibition overcomes resistance to molecular targeted therapy in BRAFV600E mutant high-grade glioma.

  2022cites this paper
• Human peripheral blood mononuclear cells: A review of recent proteomic applications

  2022cites this paper
• HSP90/IKK‐rich small extracellular vesicles activate pro‐angiogenic melanoma‐associated fibroblasts via the NF‐κB/CXCL1 axis

  2022cites this paper
• Molecular Pathways and Mechanisms of BRAF in Cancer Therapy.

  2022cites this paper
• What, if Any, Role Is There for BRAF-Targeted Therapy in BRAF-Mutant Melanoma?

  2022cites this paper
• Design, synthesis, biological evaluation and molecular docking study of 2,4-diarylimidazoles and 2,4-bis(benzyloxy)-5-arylpyrimidines as novel HSP90 N-terminal inhibitors

  2022cites this paper
• Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins.

  2022cites this paper
• The heat shock response and small molecule regulators.

  2021cites this paper
• Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy

  2021cites this paper
• PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas

  2021cites this paper
• The HSP90 inhibitor, XL888, enhanced cell apoptosis via downregulating STAT3 after insufficient radiofrequency ablation in hepatocellular carcinoma.

  2021cites this paper
• The role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma (Review).

  2021cites this paper
• A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas

  2021cites this paper
• Advanced Melanoma: Resistance Mechanisms to Current Therapies.

  2021cites this paper
• Targeted mass-spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP kinase, and AKT signaling

  2021cites this paper
• The role of heat shock proteins in neoplastic processes and the research on their importance in the diagnosis and treatment of cancer

  2021cites this paper
• HSP90 Inhibition and Modulation of the Proteome: Therapeutical Implications for Idiopathic Pulmonary Fibrosis (IPF)

  2020cites this paper
• Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.

  2020cites this paper
• A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer

  2020cites this paper
• Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies

  2020cites this paper
• HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer

  2020cites this paper
• AhR and Cancer: From Gene Profiling to Targeted Therapy

  2020cites this paper
• Extracellular Chaperones as Novel Biomarkers of Overall Cancer Progression and Efficacy of Anticancer Therapy

  2020cites this paper
• Evolving impact of long-term survival results on metastatic melanoma treatment

  2020cites this paper
• Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review

  2020cites this paper
• An updated patent review of anticancer Hsp90 inhibitors (2013-present)

  2020cites this paper
• 1 Roles of Extracellular Vesicles ( EVs ) carrying HSPs in 2 Cancer Biomarkers , Immune Surveillance , and 3 Immune Evasion 4

  2019cites this paper
• Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy

  2019cites this paper
• 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes

  2019cites this paper
• The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma

  2019cites this paper
• Combination therapies with HSP90 inhibitors against colorectal cancer.

  2019cites this paper
• Chaperoning STAT3/5 by Heat Shock Proteins: Interest of Their Targeting in Cancer Therapy

  2019cites this paper
• Role of HSP90 Inhibitors in the Treatment of Cancer

  2019cites this paper
• Heat Shock Proteins in Glioblastoma Biology: Where Do We Stand?

  2019cites this paper
• Inhibitors of HSP90 in melanoma

  2019cites this paper
• Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune Evasion

  2019cites this paper
• Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside

  2019cites this paper
• R

  2019influential citation
• Targeted Therapies for BRAF-Mutant Metastatic Melanoma

  2018cites this paper
• Forestalling BRAF-Inhibitor Resistance in a Shocking Way

  2018influential citation
• Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma

  2018cites this paper